🔎 Trials Near Me

Beranda › Limfoma Sel B Besar Difus › Oregon

Uji klinis Limfoma Sel B Besar Difus di Oregon

15 studi untuk Limfoma Sel B Besar Difus mencari peserta di lokasi di Oregon.

Kota di Oregon

Teks studi resmi (Bahasa Inggris)

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06649812

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

  • Providence Portland Medical Center ( Site 0120), Portland
  • Providence Oncology and Hematology Clinic Westside ( Site 0179), Portland
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06890884

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

  • OHSU Knight Cancer Institute, Portland
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT06784167

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

  • Oregon Health & Science University (OHSU), Portland
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07226843

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Oregon Health and Science University ( Site 1004), Portland
Menerima pesertaFase 1/2
6 Months – 25 Years · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT06395103

Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

  • Oncology Associates of Oregon, P.C, Eugene
  • Providence Portland Medical Center, Portland
  • Providence St. Vincent Medical Center, Portland
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT06806033

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

  • Oncology Associates of Oregon, Eugene
  • Oregon Health and Science University, Portland
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Agu 2026 · NCT06500273

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • Oregon Health & Science University, Portland
Menerima pesertaFase 1/2
Usia 13 hingga 90 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06533579

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

  • Oregon Health and Science University Knight Cancer Institute, Portland
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT06116110

DALY II USA/ MB-CART2019.1 for DLBCL

  • Oregon Health and Science University Knight Cancer Institute, Portland
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Jul 2026 · NCT04792489

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

  • OHSU Knight Cancer Institute, Portland
Menerima pesertaFase 1/2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 7 Jul 2026 · NCT06249191

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

  • Providence Newberg Medical Center, Newberg
  • Providence Willamette Falls Medical Center, Oregon City
  • Providence Portland Medical Center, Portland
  • dan 2 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Feb 2026 · NCT05633615

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

  • Providence Newberg Medical Center, Newberg
  • Providence Willamette Falls Medical Center, Oregon City
  • Providence Portland Medical Center, Portland
  • dan 1 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Okt 2025 · NCT05890352

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

  • Oregon Health & Science University, Portland
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2025 · NCT05780034

Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.